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Neuroprotection plays a crucial role in everyday life, maintaining a clean 
environment in the central nervous system to allow for normal functioning. In 
Alzheimer’s disease and other neurodegenerative disorders, neuroprotection 
may have two roles. Under standard circumstances, the immune system protects 
the CNS, but sometimes it can exacerbate the pathophysiology of some diseases 
through neuroinflammation leading to further degeneration. Alzheimer’s disease is 
fast getting out of control, with no new approvals in therapeutics since 2003, and of 
those approved, all target symptomatic treatment. Initiated by a microglial response 
to Aβ plaques, therapeutic development should focus on the amyloid cascade as a 
neuroprotective measure for Alzheimer’s disease. This chapter will examine the 
status of the types of therapeutics in clinical trials for Alzheimer’s disease, offering 
insights into peptides as an area of opportunity for neuroprotection and detailing 
considerations for the use of peptides in Alzheimer’s disease.
Keywords: Alzheimer’s disease, peptides, neuroinflammation, therapeutic 
development, CNS indications
1. Introduction
The central nervous system (CNS) consists of the brain and spinal cord, playing 
the role of control centre in the body. It is responsible for sending and integrating 
signals from around the body and coordinating activity. Protecting the CNS is 
crucial to sustaining life. Without this system, normal day-to-day functions such as 
breathing and eating would be compromised. Arguably, the most important organ 
in the CNS is the brain. This is protected from external physical injury by the skull 
and meninges, which provide a buffer against forceful trauma to the head. How 
does the brain protect itself from internal injury, such as a microbiological threat 
or other small molecules that invade the sterile environment? Bacteria, viruses and 
misfolded proteins are as much of a threat as physical impacts. However, there is no 
durable exterior to protect from these internal attacks. The next line of defence is 
the immune system, a complex network of specialised cells that aim to protect the 
body against these biological threats.
The immune response is key to maintaining the delicate environment of the 
CNS. However, the neuroprotective properties of the immune system may also be 
detrimental to the surrounding neurons. Immune cells release chemical mediators 
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such as cytokines and histamine to damage foreign cells, but these mediators also 
damage sensitive structures that make up the brain. This process occurs in disorders 
where degeneration of cellular tissue in the brain is present. Disorders such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) 
and Amyotrophic Lateral Sclerosis (ALS) all exhibit progressive degeneration of 
specific neuronal cell populations [1, 2]. All four diseases are commonly found to 
exhibit misfolding, aggregation and accumulation of specific proteins. This hall-
mark feature is now widely accepted as a possible cause for these diseases and other 
neurodegenerative disorders [3–5]. Deposition of amyloid-forming proteins func-
tions as the initiating step for neuroinflammation [6] activating pattern recognition 
receptors (PRRs) on microglia, the resident macrophages in the brain [6, 7]. To 
protect the brain, microglia recognise fragments of these misfolded proteins and 
secrete cytokines and chemokines. The release of these pro-inflammatory immu-
nomodulators mediates neuroinflammation, attracting other immune cells such 
as astrocytes and perivascular macrophages to aid in innate immunity [8]. In most 
cases, activated microglia will clear the build-up of the pathogenic proteins resolv-
ing the immune response and subsequent inflammation.
In a typical immune response where resolution is achieved, clearance of 
the localised inflammation allows the surrounding tissue to return to normal 
conditions. When the immune response is not resolved, inflammation persists 
in the local area, potentially becoming toxic to neighbouring cells. Prolonged 
inflammation in a sensitive environment such as the CNS is highly likely to 
cause damage to neurons and other nearby cells, leading to local degeneration of 
tissue. Damage-associated molecular patterns (DAMPs) released from neurons 
in the inflamed area are recognised by PRRs on primed microglia. This further 
stimulates the release of pro-inflammatory molecules [9]. This persistent self-
propagating cycle of inflammation and necrosis causes the chronic inflammation 
that exacerbates the pathology of the disease. The notion that neuroprotection 
does more damage than it prevents has been explored recently, with some pro-
posing that inflammation is the causative agent of neurodegeneration [10, 11]. 
To prevent neurodegeneration found in diseases like AD, neuroprotective thera-
peutics must be developed in order to prevent further inflammation and damage 
from occurring.
1.1 Alzheimer’s disease as a neuroinflammatory disorder
Alois Alzheimer first discovered clusters of abnormal protein built up in the 
cerebral cortex of a patient in 1906. Alzheimer described these clusters as “thick 
bundles [that] appear at the surface of the cell”, noting specifically that neurons in 
the upper layers of tissue had “disappeared” [12]. These bundles were later identi-
fied as the two major hallmarks of AD, hyperphosphorylated tau and aggregated 
amyloid-beta (Aβ). Alzheimer also noted glial cells clustered around the plaques, 
concurrent with the theory of an immune response to the extracellular deposits 
of Aβ plaques and cellular death. In 2019, we are still no closer to mapping out 
the nature of this disease than Alois was in 1906, with the pathophysiology of the 
disease still debated: which came first, the tau or the plaques? There have been sev-
eral hypotheses considered over the nature of the disease; however, the two major 
hallmarks remain the most probable causes.
To describe the basis of the two major hypotheses is easy; the amyloid cascade 
involves the cleavage of a transmembrane protein known as amyloid-precursor 
protein (APP) by the aspartic-acid protease beta-site amyloid precursor protein 
cleaving enzyme 1 (BACE1), which leads to the extracellular aggregation of a 
peptide called Aβ, whereas the neurofibrillary tangle (NFT) theory posits that AD 
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is caused by the hyperphosphorylation of tau, a soluble microtubule-associated 
protein that can aggregate intracellularly into NFTs.
Before establishing the effects of a therapeutic for neuroprotection in AD, the 
causative agent of neuronal death needs to be identified. Examining both hypoth-
eses in detail reveals that the deposition of Aβ plaques has more of an effect on 
NFT formation than hyperphosphorylation of tau has on amyloid build-up [13, 14]. 
Arguments for both options are common place in discussion about AD; however, 
there are some key facts on why Aβ plaques are crucial in the development of 
neurodegeneration, and therefore the symptoms of AD. In transgenic mouse 
models, it has been shown that NFT formation succeeds Aβ deposition extracellu-
larly [15, 16]. As a causal agent, tau is seen in other diseases such as frontotemporal 
lobar degeneration, progressive supranuclear palsy and Pick’s disease. All of which 
form tau aggregates without an onset of Aβ deposition. The distinct immune 
response from Aβ plaque deposition indicates that the amyloid cascade is the 
driving factor of neurodegeneration in AD [10]. From a neuroprotective stand-
point, preventing the amyloid cascade from generating and depositing Aβ plaques 
seems the most probable option for prevention of neurodegeneration from chronic 
neuroinflammation.
2. Therapeutics for Alzheimer’s disease: past, present and future
In a 20-year period from 1998 to 2017, a total of 146 drugs in clinical trials 
were halted or had not received approval by the FDA [17]. In that same time, four 
cognitive-enhancing therapeutics had been approved, giving some hope that there 
is a chance to identify a therapeutic for AD. Therapeutics in the AD clinical trial 
pipeline are split into two major classes of mechanism of action (MOA): symptom-
atic treatments and disease-modifying therapies (DMTs). Symptomatic treatments 
aim to alleviate symptoms that are present with the onset of the disease easing the 
burden on the affected individuals. There are currently five therapies that have been 
approved for use in patients that exhibit symptoms derived from neurotransmitter 
disturbance in mild to severe cases of AD. Suppressing symptoms such as memory 
loss and cognitive decline do not address the underlying nature of the disease [18]. 
Symptomatic treatments are beneficial for family and friends, demonstrating 
modest and consistent benefits for cognition. However, the underlying cause of 
the disease remains unchanged in these therapies where the disease progresses into 
a more severe state. DMTs are treatments that alter the pathology of the disease, 
changing the long-term course of the disease. A large proportion of DMTs targets 
the major hallmarks of AD, NFTs and Aβ formation. Other DMTs are present that 
target alternative aspects of the disease; however, these alternative targets are 
mostly downstream effects of NFTs or Aβ plaques. Of major interest are DMTs that 
target the amyloid cascade, their primary goal is to reduce plaque load, clear plaque 
depositions, or reduce inflammation. The nature of this MOA is of a neuroprotec-
tive stance, theoretically with the ability to reduce the amount of neurodegenera-
tion that occurs due to chronic inflammation from Aβ seeding in the extracellular 
space.
As of February 2019, 132 therapeutics were in clinical trials for AD, 96 of 
those classed as DMTs presenting an increase of 25 DMTs from 2018 [19, 20]. 
Therapeutics labelled as neuroprotective, anti-inflammatory and anti-amyloid 
in the 2019 cohort of clinical trials will be described as neuroprotective DMTs as 
they all target the amyloid cascade as the priming step of neuroinflammation. 
Neuroprotective DMTs are described as either prophylactic treatments or disease-
clearing treatments. Prophylactic treatment of AD aims at preventing the onset 
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of the disease by targeting the steps prior to amyloid deposition aiming to prevent 
the activation of microglia and subsequent neuroinflammation. Disease-clearing 
therapeutics target plaques deposited into the extracellular space. They focus on 
removing plaques and debris to prevent chronic inflammation. There is no clear 
current trend in neuroprotective DMTs, with a broad selection of therapeutics 
covering different targets from amyloid clearance using antibodies or vaccines to 
mark areas for the immune system, anti-aggregation of Aβ fibrils, or preventing the 
production of Aβ fragments by targeting BACE1 or alpha secretase.
2.1 Lessons from previous clinical trials
With such a broad range of therapeutics in clinical trials, it would be easy to 
assume that we are close to finding a treatment for AD, but we are not. In the 
20 years spanning 1998 to 2017, almost 150 therapeutics in clinical development 
had stopped or not received regulatory approval [17]. The FDA approved only four 
therapeutics in that time leaving a lot to learn from past failures. Neuroprotective 
DMTs made up 34% of the therapeutics discontinued in this time, leaving in their 
wake a plethora of lessons that can be applied to upcoming therapeutics [21]. A shift 
in development from the conventional small molecule drug (SMD) to a biological 
approach has shown benefits. Increased knowledge on the effects of more potent 
and specific therapeutics has led to the identification of new targets for therapeutic 
development, specifically the amyloid cascade. Of the therapeutics active in clinical 
trials in the 15 years from 2005 to 2019, 79 targeted the amyloid cascade in a disease-
modifying mechanism (Table 1). Moreover, of the 79 clinical trials, 20 have been 
discontinued (Table 1).
2.1.1 Types of therapeutics
A shift in the type of therapeutic used in AD has given insights into how targets 
respond to certain molecules. A common issue encountered with amyloid targeting 
therapeutics is specificity, with off-target effects halting a few large-scale trials [22]. 
There are two major molecular classes present in amyloid targeting DMTs: small 
molecule, low molecular weight entities including chemical drugs and peptides, and 
biologics, larger structures such as proteins and antibodies.
2.1.1.1 Small molecular entities
Thought of as the traditional form of therapeutic, small molecular entities 
(SMEs) are typically chemical in nature and mostly target molecules with deep 
catalytic channels or clefts such as enzymes or receptors [23]. The nature of these 
SMDs is to bind to the target and exert its effect, doing so until there is no more 
target available for binding or the drug is cleared from the body. This overzealous 
technique of SMDs poses the risk of long-term modulation on the target, whether 
it be positively or negatively, regardless of whether the disease state improves or 
not [24].
The main target of an SME is commonly found in biological processes where a 
high amount of regulation is required, in the form of either enzymes or receptors 
[25]. The interaction that SMEs target is between an enzyme or receptor and its 
respective substrate, all of which are proteins. Referred to as protein–protein inter-
actions (PPIs), they have gained popularity as a target for therapeutic intervention 
due to the control these interactions have on biological processes. Many PPIs have 
been identified as candidates targeting diseases similar to AD where a biological 
process has been altered resulting in disease [25].
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NCT number Drug name Phase Status Start date Completion date
NCT00303277 Simvastatin & 
Pravastatin
IV C 08/2002 04/2005
NCT00479219 GSI-953 I C 05/2007 10/2007
NCT00765115 LY450139 I C 07/2006 09/2007
NCT0083808 LY2811376 I C 12/2008 06/2009
NCT00733642 PF-04360365 I A, NLR 08/2008 07/2009
NCT01125631 PF-04360365 I C 05/2010 08/2011
NCT01148498 Solanezumab II C 08/2010 08/2012
NCT01482013 HPP854 I D 10/2011 03/2012
NCT00464334 V950 and 
ISCOMATRIXTM
I C 03/2007 01/2012
NCT00411580 CAD106 I C 06/2005 12/2008
NCT00945672 PF-04360365 II C 08/2009 06/2011
NCT01547169 Insulin detemir II C 03/2011 12/2012
NCT00500500 EGb 761 II D 07/2005 04/2008
NCT00739037 PAZ-417 I D 08/2008 12/2008
NCT01568086 Affitope AD03 I D 12/2011 10/2013
NCT01661673 EVP 0962 II C 11/2012 10/2013
NCT00812565 Immune Globulin II C 02/2009 09/2010
NCT00857506 Florbetapir F 18 II C 01/2009 12/2011
NCT00397891 Bapineuzumab I C 10/2006 02/2010
NCT01035138 Semagacestat III C 12/2009 04/2011
NCT01669876 Anatabine II D 08/2012 02/2015
NCT01978548 Atabecestat I C 12/2013 04/2015
NCT02061878 Bexarotene I C 08/2014 11/2014
NCT00486044 Simvastatin II C 02/2005 06/2009
NCT00711321 Affitope AD02 & 
Aluminium hydroxide
I C 11/2008 04/2010
NCT01093664 Affitope AD02 & 
Aluminium hydroxide
I C 10/2009 07/2010
NCT01357629 Affitope AD02 & 
Aluminium hydroxide
I D 07/2011 11/2013
NCT00633841 Affitope AD02 & 
Aluminium hydroxide
I C 02/2008 09/2009
NCT01782742 Bexarotene II C 02/2013 12/2014
NCT02323334 LY3202626 & 
Itraconazole
I C 12/2014 02/2016
NCT00722046 Ponezumab II C 12/2008 08/2011
NCT00956410 Amilomotide II C 09/2009 06/2011
NCT00762411 Semagacestat III C 09/2008 04/2011
NCT01097096 Amilomotide II C 03/2010 12/2012
NCT01928420 Pinitol II C 04/2007 06/2014
NCT00329082 Solanezumab II C 05/2006 05/2008
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NCT number Drug name Phase Status Start date Completion date
NCT01600859 Elenbecestat I C 07/2012 10/2013
NCT01297218 hMSC Therapy I C 02/2011 12/2011
NCT01193608 AAB 003 I C 09/2010 10/2013
NCT02260674 Atabecestat II C 11/2014 06/2016
NCT02033668 GSK 933776 I C 01/2014 07/2014
NCT01424436 GSK 933776 I C 05/2010 12/2011
NCT02576639 Umibecestat II C 08/2015 03/2016
NCT00904683 Solanezumab III C 05/2009 06/2012
NCT02386306 GC 021109 I C 02/2015 10/2015
NCT01595646 Insulin detemir II C 11/2011 03/2015
NCT01561430 LY 2886721 I/II D 03/2012 Jun 2013
NCT02551809 UB 311 II C 10/2015 08/2018
NCT03417986 Thiethylperazine II A, NLR 11/2017 07/2021
NCT01056965 Davunetide I C 01/2010 12/2012
NCT01428453 Rilapladib II C 07/2011 02/2013
NCT02036645 MEDI 1814 I C 02/2014 09/2016
NCT01397578 Crenezumab II C 07/2011 04/2014
NCT01127633 Solanezumab III D 11/2010 02/2017
NCT02760602 Solanezumab III D 06/2016 05/2017
NCT01900665 Solanezumab III D 07/2013 02/2017
NCT02080364 Azeliragon III D 04/2015 06/2018
NCT01807026 LY 2886721 I C 03/2013 05/2013
NCT02462161 Insulin aspart I C 03/2015 04/2019
NCT02899091 CB-AC 02 I/II R 09/2016 12/2021
NCT02614131 LY 2599666 & 
Solanezumab
I D 12/2015 12/2016
NCT02406027 Atabecestat II D 07/2015 06/2018
NCT02051608 Gantenerumab III A, NLR 03/2014 04/2021
NCT03114657 Crenezumab III D 03/2017 06/2019
NCT02565511 Amilomotide & 
Umibecestat
II/III D 11/2015 03/2025
NCT01760005 Atabecestat & 
Gantenerumab & 
Solanezumab
II/III D 12/2012 03/2021
NCT01224106 Gantenerumab III A, NLR 11/2010 08/2020
NCT01966666 TPI 287 I A, NLR 11/2013 11/2019
NCT00594568 Semagacestat III C 03/2008 05/2011
NCT02719327 E-EPA II/III R 06/2017 11/2021
NCT02956486 Elenbecestat III D 10/2016 11/2023
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Analysis of SMEs targeting PPIs has shown that they do not observe standard 
drug-like properties, specifically surrounding their size, hydrophobicity and speci-
ficity [26, 27]. These properties all show mild increases, compared to conventional 
SMDs, proving that the chemistry of PPIs requires molecules to be selected more 
carefully rather than selecting the molecule with the highest potency.
2.1.1.2 Biologics
Biologics fill the void of the upper end of the molecular weight scale, made up 
of antibodies, proteins and enzymes. Biological therapeutics like antibodies and 
vaccines aim to modulate the immune system to clear various threats from the body. 
Other therapies involve the replacement of an important molecule in a biologi-
cal process, such as hormone replacement therapy (HRT) or lactose intolerance. 
Replacement therapies use therapeutics that mimic proteins in a healthy individual, 
usually using recombinant technology to produce the protein in different biological 
models.
The PPIs mentioned above have important regulatory roles in biological pro-
cesses, keeping them in check as cell signalling molecules [28]. Biological interven-
tion with molecules that mimic or stop these interactions enables control over 
biological pathways similar to SMDs, however, giving the pathway some control 
over feedback [24]. Antibodies are an excellent example of controlling the immune 
system in AD to remove the build-up of deposited plaques, while allowing the body 
to exert control over the reaction of the immune response to these antibodies. This 
shows the benefit of using biologics in the development of therapeutic options for 
AD and other diseases.
A common issue that has arisen in the therapeutic development of biologics is 
the bioavailability and half-life of the therapeutic. Biologics are not well known for 
high bioavailability, particularly where the oral route is concerned, an issue that 
can be overcome using other forms of administration [29]. Following administra-
tion, biologics are subjected to proteases and harsh conditions in the stomach or 
other accessory organs that reduces the half-life dramatically [30]. Intravenous 
and intramuscular administration has improved the half-life of biologics; however, 
NCT number Drug name Phase Status Start date Completion date
NCT03036280 Elenbecestat III D 12/2016 11/2023
NCT02245737 Lanabecestat II/III D 09/2014 10/2018
NCT03443973 Gantenerumab III R 08/2018 03/2023
NCT03444870 Gantenerumab III R 06/2018 03/2023
NCT00299988 Immune Globulin II D 02/2006 04/2010
NCT02600130 hMSC 
Therapy-Longeveron
I A, NLR 10/2016 09/2020
NCT03402659 Neflamapimod II C 12/2017 07/2019
NCT03117738 Adipose SC 
therapy-Anterogen
I/II C 04/2017 06/2019
Abbreviations: A, Active; NLR, no longer recruiting; C, Completed; D, Discontinued. NOTE: 79 trials were identified 
as amyloid targeting as of January 9, 2020, according to https://adisinsight.springer.com.
Table 1. 
Amyloid targeting clinical trials from 2005 to 2019.
Neuroprotection - New Approaches and Prospects
8
modification to the structure of the therapeutic may be required to reach the target 
from the blood stream or the tissue at the site of injection. Although there are 
common issues regarding ideal therapeutic properties of biologics, new technology 
is improving every day allowing therapeutic development of biologics to overcome 
what seems to be simple obstacles.
2.1.2 Targets of the amyloid cascade
2.1.2.1 Inflammation
As the step preceding neurodegeneration, inflammation is a clear target for 
therapeutic intervention. Neuroinflammation has been a target in therapeutic 
development after the increasing recognition that glial activation is an important 
step in the process of neurodegeneration. Therapeutics targeting neuroinflam-
mation have been evaluated in previous cohorts of clinical trials, all producing 
similar results of ineffectiveness at slowing cognitive decline [31]. The principle of 
anti-inflammatory targeting aims to prevent the off-target damage to neighbouring 
neurons, delaying the onset of neurodegeneration. However, without remov-
ing the stimulus causing neuroinflammation, therapeutics are fighting a losing 
battle. Factors such as rate of cognitive decline, severity of the neuroinflammatory 
response, and disease state play a role in anti-inflammatory and immunomodula-
tory drug discovery proving difficult as the timing of the intervention is critical 
[32]. Anti-inflammatory therapeutics made up 16% of therapeutics in clinical trials 
in 2019, many repurposed for AD [19]. As a sole therapeutic intervention for AD, 
anti-inflammatories are not ideal. Combined therapy using anti-inflammatories 
and a disease-clearing therapeutic will likely show a high rate of success in alleviat-
ing chronic inflammation caused by AD.
2.1.2.2 Amyloid-β
Aβ is an attractive target for neuroprotection, with many possible angles to 
approach the underlying cause of the disease. Two methods aimed at targeting 
Aβ plaques have been employed in clinical trials: immunotherapy, targeting the 
plaques for removal by the immune system using a vaccine or monoclonal antibod-
ies (mAbs), and anti-aggregation, preventing the Aβ fragments from forming the 
plaques. In 2019, nine immunotherapies were part of clinical trials: three active 
immunotherapies (vaccines), CAD106, ABvac40 and GV1001, and six passive 
immunotherapies (mAbs), aducanumab, crenezumab, gantenerumab, solan-
ezumab, LY3002813 and LY3372993 [19].
Thoroughly tested in animal models, Aβ vaccines exhibit the ability to 
prevent the formation of new Aβ plaques and contribute to the clearance of 
pre-deposited plaques [33]. Immunising an individual to Aβ grants the long-term 
effects of antibody production. However, immunisation can be difficult where 
adverse reactions in older individuals may occur due to inconsistent or lack of an 
immune system, as well as selecting a specific epitope that will not target similar 
structures [34]. Clinical trials into AN1792, an adjuvant vaccine of the full-length 
Aβ peptide and QS-21, were stopped due to development of meningoencephalitis 
in some patients [35]. Second-generation anti-Aβ vaccines such as CAD106 
have proven to be efficacious in phase 2 clinical studies, eliciting Aβ-specific 
antibodies and showing long-term safety promising to be a valuable therapeutic 
option [36].
Passive immunotherapies have a major advantage over Aβ immunisation in 
that there is a consistent antibody titre [34]. Initial intravenous administration 
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of immunoglobulin preparations containing high levels of human anti-Aβ42, 
which showed a significant improvement in cognition and lower levels of Aβ 
[33]. However, similar to the other discontinued anti-Aβ mAb therapies, large-
scale testing proved efficacy to be low or non-existent. A risk found in trials with 
Bapineuzumab was the presence of abnormalities after imaging the brain, identify-
ing the onset of vasogenic oedema in 3 of the 10 participants. These abnormali-
ties were coined as ARIA-E, amyloid-relating imaging abnormalities-vasogenic 
effusions, and are seen as a risk in large-scale studies of mAb therapies [37]. Many 
mAbs in 2019 are still plagued with these obstacles, presenting safety concerns 
surrounding ARIA-E, although some mAbs in Phase 2/3 or 3 trials are looking closer 
than ever at slowing the progression of AD.
As a target class, combined therapy of immunotherapeutics and anti-aggregates 
stand the highest chance of clearing deposited and newly generated Aβ fragments. 
Aggregation of Aβ monomers only make it more difficult to clear from the extracel-
lular space with neuroprotective mechanisms naturally clearing monomers that 
build-up over time. From this perspective, Aβ is targeted as both monomers and 
plaques. Solanezumab targets Aβ monomers before they can aggregate. Targeting 
the causal feature of amyloid-based microglial activation, anti-aggregates prevent 
the conversion of Aβ monomers into oligomers or fibrils [38]. Many natural and 
synthetic compounds have been identified as potential anti-aggregates for Aβ; 
however, the only anti-aggregate for amyloidogenesis in clinical trials in 2019 is a 
combination therapy of polyphenol extract from grapeseeds and resveratrol [19]. 
The current cohort of anti-aggregates is not indicative of knowledge of the field, 
with other compounds such as epigallocatechin-3-gallate and curcumin showing 
promising results for both anti-aggregation and other purposes [39].
2.1.2.3 Secretase inhibitors
Modulating the upstream step of plaque formation provides an encouraging 
target as prevention of deposition of Aβ fragments may stop the neuroinflamma-
tory response before it starts. A “one size fits all” therapy for secretase modulation 
is not possible as all three secretase enzymes play different roles in the genera-
tion of Aβ fragments, each requiring a different form of modulation specific to 
their role in the processing of APP.
2.1.2.3.1 Gamma secretase
Inhibitors of BACE1 and gamma secretase have thus far showed limited Aβ 
clearance in clinical trials, even after demonstration of excellent inhibition in 
preclinical animal models [40]. Studies into gamma secretase found that it was the 
last step in Aβ fragment generation and an ideal target to prevent the build-up of 
fragments and formation of plaques [41]. Semagacestat was identified as potential 
drug candidate for clinical trials in decreasing Aβ levels, only after Phase III in 
the IDENTITY trials was it found to have adverse effects on Notch signalling [42]. 
Identified as a drug with a higher selectivity for APP over Notch in preclinical 
studies, Avagacestat was another gamma secretase inhibitor that showed similar 
effects to Semagacestat forcing the discontinuation of the trials due to adverse 
dose-limiting effects [43]. The adverse effects and lack of efficacy had quashed 
further research into gamma secretase inhibitors; however, a new look into gamma 
secretase as a target has identified that it is available for modulation, specifically 
altering the cleavage site of the enzyme. NGP 555 is a promising SME gamma 
secretase modulator that has showed promising results in vivo, significantly lower-
ing levels of Aβ42 through a shift of cleavage site in gamma secretase [44].
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2.1.2.3.2 Alpha secretases
Alpha secretase as a therapeutic target for AD offers a novel approach of upregu-
lating cleavage of APP rather than preventing it. By cleaving APP within the Aβ 
domain, alpha secretase prevents the generation of Aβ fragments instead releasing 
non-toxic p3 peptide following gamma secretase cleavage [45]. Modulation of alpha 
secretase is expected to increase its activity and reduce levels of Aβ, potentially 
increasing the levels of a neuroprotective product of alpha secretase cleavage of 
APP, sAPPα [46]. Alpha secretases belong to the ‘a disintegrin and metalloprotease’ 
(ADAM) family, which are found to play roles in cell adhesion, migration, prote-
olysis and signalling [47]. ADAM10 was found to be the alpha secretase relevant 
to APP cleavage in neurons, making it the target of modulation in AD [48]. Two 
therapeutics that have undergone clinical trials showing potential as alpha secre-
tases enhancers are etazolate (EHT-0202) and bryostatin-1. Both stimulate alpha 
secretase to increase generation of sAPPα [49]. The potential of alpha secretase 
enhancers as a therapeutic for AD is likely. However, studies into the effects of 
enhancers on the other substrates of ADAM10 are required to identify any possible 
adverse effects [50].
2.1.2.3.3 BACE1
Targeting BACE1 for therapeutic development in AD is ideal, as it is the deter-
mining step in the generation of Aβ fragments. Inhibition of BACE1 has shown to 
decrease levels of Aβ plaques. Studies in mouse models have proven that by remov-
ing BACE1 there is no generation of Aβ fragments, and subsequently no neurode-
generation and loss in cognitive abilities [51].
Since it was discovered to play a role in AD in 1999, BACE1 has been thoroughly 
researched as a potential target for AD. BACE1 has been an elusive target for inhibi-
tors, its location in the brain, size of the active site, and similarity to other aspartic 
proteases making it difficult for the ideal therapeutic to be developed [52]. Initial 
inhibitors of BACE1 were non-cleavable peptide-based analogues, designed on the 
amino acid sequence of APP, which showed excellent inhibitory effects on BACE1. 
However, the size was too large to exhibit in vivo benefits, although ideal for the 
active site [53]. The development of SMEs for BACE1 renewed hope in the use of the 
aspartic protease as a target, hoping to increase blood–brain barrier (BBB) pen-
etration and bioavailability that were identified as issues with the first-generation 
BACE1 inhibitors. From there, the hunt for a BACE1 inhibitor began with multiple 
classes of inhibitors being developed in an attempt to find the ideal therapeutic.
In a similar pattern to other amyloid therapies, BACE1 inhibitors in other trials 
were halted or discontinued due to lack of efficacy or off-target effects. Only two 
BACE1 inhibitors were in the 2019 cohort of clinical trials: CNP520, discontinued 
in July 2019 due to worsening of cognitive function, and E2609, discontinued in 
September 2019 due to unfavourable risk–benefit ratio [54, 55]. Both compounds 
joining the list of lessons learnt from BACE1 inhibitors, along with Lanabecestat, 
Atabecestat and Verubecestat. All of which proved excellent in reducing Aβ; how-
ever, translation into clinical trials was not as smooth, lacking efficacy or displaying 
off-target effects [56].
2.2 Improving therapeutics or target choice
With no current curative treatments for AD available, previous cohorts of clini-
cal trials are missing something vital. The types of therapeutics used and targets 
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available explained above show that therapeutic discovery is not a simple task, 
particularly in a disease as complex as AD. The ideal neuroprotective therapeutic 
for combating AD is one that targets the initiating steps of amyloid development 
with high specificity and potency, while not disrupting other biological processes. 
An attractive initiating step of amyloid development is BACE1, discussed above 
as a promising target to prevent the generation of Aβ fragments responsible for 
the activation of microglia and subsequent development of neurodegeneration. 
Previous attempts at inhibiting BACE1 have shown mixed and unfavourable 
responses of properties such as specificity, bioavailability and efficacy. Both biologi-
cals and SMEs cannot fill the requirements of such a specific therapeutic, requiring 
a molecule that has the ideal properties of both. Such a molecule is already being 
explored in therapeutic development for AD although it is still in its infancy as a 
class of therapeutic molecule for AD. Peptides are becoming more attractive as a 
therapeutic to target BACE1 with new technology altering their structure to better 
fit the required properties. Such research promises to pave new and exciting ways to 
developing refined peptide inhibitors of BACE1 with high efficacy and specificity, 
and thus prepare novel reagents for the prophylactic treatment of AD in the near 
future.
3. New outlook for Alzheimer’s disease
3.1 What are peptides?
Peptides are small molecular biologicals that play a major role in the body as 
signalling molecules. Naturally occurring peptides in humans are commonly called 
hormones, acting as messengers utilising the blood stream and other extracellular 
spaces to regulate the many biological processes that keep us going [57]. Two of 
the most well-known peptides are glucagon and insulin, both playing large roles in 
homeostasis of blood-glucose levels. These hormones act on blood-glucose levels 
by targeting accessory organs and stimulating glucose production or glycogen 
storage, respectively. The action of glucose and insulin is a classic example of how 
peptides work in the body with high specificity and rapid onset of effect. Although 
commonly linked to hormones, peptides are also used as neurotransmitters, anti-
infectives and growth factors [58].
Peptides range in length from 10 to 50 amino acids long, and can have a mass 
of up to 5 kDa, putting them between SMEs and proteins in terms of size and 
weight. In vivo, natural peptides are highly efficacious and selective with limited 
off-target effects, transient at most for those that exist [59]. Their ability to act 
as signalling molecules both extracellularly and intracellularly displays the range 
of therapeutic opportunity that peptides exhibit. Following the discovery of 
peptides playing large roles in homeostasis in the body, research turned towards 
identifying and isolating certain peptides that were linked to diseases. To con-
tinue with the example of insulin, the development of insulin as a therapeutic 
comes from the identification of individuals lacking a “pancreatic secretion” in 
the early 1900s, where insulin was isolated from the pancreas of stray dogs and 
calves and used to treat a child with type I diabetes [57]. This discovery only 
fuelled the fire for further discovery and isolation of other natural peptides that 
were found to be involved in diseases, leading to the identification of over 7000 
naturally occurring peptides. Although identified, not all can be used directly as 
a therapeutic due to unbeneficial properties such as poor bioavailability and short 
half-life [58].
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3.2 Peptides as therapeutic options
The nature of tasks that peptides perform in the body makes them an  enticing 
molecule, as an opportunity to control biological processes in a similar way 
that hormones and other natural peptides control everyday life. Many consider 
peptides to be the inferior option for therapeutic development as they display 
low oral bioavailability and a tendency to be metabolised by proteolytic enzymes 
in the local environment leading to a short half-life in vivo [57]. These unfavour-
able traits are mitigated in the body through close proximity of targets to the site 
of release, sometimes in high concentrations for when multiple targets exist. 
For peptides to be successful in therapeutic applications, an intense intravenous 
dosing regimen for the patient is required to maintain an adequate load of the 
therapeutic. Although hindered by poor bioavailability and short half-life, the 
biological nature of peptides offers plenty of properties that would make them 
an ideal therapeutic for complex diseases where specificity and toxicity are of 
concern [57].
The specific nature of peptides is due to their ability to cover a larger area of the 
target site compared to SMDs, decreasing the risk of off-target effects that have 
halted previous clinical trials into AD therapeutics [60]. A benefit of peptides over 
SMDs is the relative inability to build-up toxicity due to the metabolic instability 
of the amide bonds that hold the peptide together, resulting in the release of amino 
acids that can be utilised by various systems [61]. These qualities of peptides are 
what make them ideal therapeutics for most biological process disorders, spe-
cifically those found in the CNS. The delicate environment of the CNS requires 
therapeutics that are highly specific so as not to affect the normal functioning of the 
brain, but also produce minimal toxicity to prevent damage to nearby neurons.
3.3 Peptides approved for therapeutic use
In the 36 months that spanned 2016–2018, 8 peptide therapeutics were 
approved by the FDA making up just over 6% of the drugs approved in that time 
[62]. This can be looked at in both an optimistic and pessimistic view. However, 
looking at cumulative FDA approvals given since 1980, there is no denying that 
peptides have a place in therapeutic development. In 2018, there were over 70 
peptides available for medical use in the United States, Europe and Japan, and 
more than 150 in clinical studies [63]. The most commonly used therapeutic 
peptides target biological processes in a similar way that biologics, such as 
proteins, do, replacing molecules that stimulate PPIs. Crucial hormones that were 
approved for therapeutic use are vasopressin, oxytocin, insulin, glucagon and 
corticotropin, all of which were approved last century yet still play a pivotal role 
in HRTs [63].
Currently approved peptides cover a large range of therapeutic areas, such 
as oncology, metabolic diseases, haematology, respiratory disorders and gas-
troenterology. Of the peptides approved by the FDA, only three are approved 
for CNS indications: corticotropin, approved for use in inflammatory diseases; 
glatiramer, approved for use in MS; and taltirelin, approved for use in spinocer-
ebellar degeneration. After the discovery of taltirelin in 2000, no other peptides 
have been approved for CNS indications, even though there have been over 30 
new peptides approved for other indications since [63]. This begs the question 
on whether research has moved away from peptides for CNS indications due to 
their difficulty passing through the BBB, or whether the technology is only now 
catching up.
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3.4 Future considerations for peptide therapeutics for use in CNS indications
With a variety of unfavourable characteristics, peptides require modifica-
tion prior to clinical testing. The field of peptide synthesis has improved in the 
past two decades contributing to a rise in more effective peptide therapeutics 
available for clinical trials [64]. Many traits of peptides that were initially 
unfavourable have been resolved with new techniques in peptide synthesis. 
However, there remains the large issue of bioavailability that is restricting the 
use of peptides as therapeutics for the CNS. The biological nature of peptides 
reduces their bioavailability, their size making it difficult to cross membrane 
barriers and the structure of their bonds increasing the rate of degradation 
in the gastrointestinal (GI) tract and plasma. Due to these features, most 
approved peptide therapeutics are parenterally administered, involving either 
intravenous or subcutaneous injections. Parenteral administration allows for 
the systemic distribution of a relatively large dose of the peptide providing 
high concentration of the therapeutic when it reaches its target, without having 
to cross any membrane barriers. The oral route does not allow for this as the 
conditions are acidic and tight mucosal barriers exist to protect the body from 
external threats [29].
Administration directly into the blood stream works for many indications where 
the target is easily reached through diffusion across capillary walls; however, CNS 
indications are protected from standard blood flow by the BBB. Peptides targeting 
the CNS endure this extra barrier that acts as a neuroprotective wall, preventing 
unwanted molecules from entering the sterile and sensitive environment [65]. 
Studies in transport of drugs across the BBB have shown that there are multiple 
ways that can be exploited to deliver drugs to the CNS, specifically using trans-
porter pathways that shuttle hormones such as insulin into the CNS [66]. Delivery 
of previous therapeutics for AD in clinical trials involved either disruption of the 
BBB, increasing lipid solubility of the molecules or using pre-existing transport 
systems, with mouse model studies showing effectiveness of the latter two [67]. 
An alternative route through the olfactory pathway may provide hope for deliver-
ing peptides to the CNS; however, intranasal delivery has demonstrated limited 
progress in clinical settings. Offering an attractive opportunity to bypass the BBB, 
intranasal delivery presents similar patterns in degradation to other routes of 
delivery [68].
Although an issue present in the delivery of peptides to the CNS, transport 
into the CNS is secondary to proteolytic degradation in terms of bioavailability 
of peptides, with a large proportion of peptide load being degraded before it 
can reach the target site. Widely accepted as techniques that decrease degrada-
tion is conjugation or the production of peptidomimetics, techniques used in 
peptide synthesis today. The most common conjugate for increasing bioavail-
ability of a peptide is polyethylene glycol (PEG), a molecule that has shown to 
help prevent clearance of therapeutics. PEG increases the overall size of peptide 
therapeutics, making it too large for renal clearance and hindering proteolytic 
cleavage in plasma [30]. Peptidomimetics are a modified form of the peptide 
that is biologically similar while containing unnatural amino acids or modified 
peptide bonds [69]. Through the addition of unnatural amino acids and altered 
peptide bonds, proteolytic enzymes are incapable of cleaving peptidomimetics 
due to the unnatural nature of the molecule. The process of screening the effects 
of multiple modifications to the structure of the peptide has improved with the 
development of simple screening assays, increasing the output of peptidomi-
metic therapeutics.
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4. Conclusions
As a mechanism, neuroprotection in CNS indications where protein misfolding 
occurs is detrimental, exacerbating the disease by creating inflammation in the local 
area that leads to the degeneration of nearby neurons. In the case of AD, neuroin-
flammation occurs when Aβ plaques are recognised by circulating microglial cells, 
initiating an immune response and releasing pro-inflammatory molecules that lead 
to the neurodegeneration that is found in patients with AD. The neuroprotective 
response of microglia in effect begins the deterioration of the brain, calling for 
therapeutic intervention to aid in neuroprotection.
Current therapeutics used as therapy for AD are all neuromodulatory, address-
ing the symptoms related to the disease instead of the underlying mechanism. 
About 73% of the current cohort of therapeutics in clinical trials for AD is DMTs, 
indicating the need for a therapeutic that either slows or stops the progression of the 
disease. DMTs targeting the amyloid cascade are of particular interest from a neu-
roprotective standpoint due to Aβ plaques initiating neuroinflammation. Targeting 
inflammation and Aβ plaques and fragments will only slow the progression of the 
disease requiring a more robust target that can stop disease progression. The role 
of BACE1 in Aβ generation provides an ideal target for therapeutics although it has 
proved elusive in the past, with trials into SMD inhibitors for BACE1 being halted 
due to safety concerns from off-target effects.
To develop an ideal therapeutic for BACE1, a molecule that lies somewhere 
between SMEs and biologics is required. Peptides offer attractive properties from 
both classes of therapeutic specifically a relative lack of toxicity and great specific-
ity, both of which are ideal for combating CNS indications. Although peptides are 
seen as inadequate for use as therapeutics, many approved peptide therapies have 
shown the ability of peptides to be modified, improving qualities that were lacking 
initially. With further advancements in the field of peptide synthesis and modifica-
tions, the number of peptide therapeutics in clinical trials, not just for AD but other 
indications, will likely increase. Similarly, the number of approved therapies, offer-
ing a promising outlook for diseases where therapeutic needs are currently unmet, 
is likely to increase.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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